Antimicrobial Dressings for Burn Wound Infection Control

描述（由申请人提供）：由于估计有200万人遭受烧伤，美国每年发生100，000 - 300，000例住院治疗。在这200万人中，有12,000多人最终将死于烧伤相关的感染。事实上，感染是烧伤患者死亡的最大原因。烧伤伤口感染可以追溯到几个来源，包括：患者自己的皮肤和胃肠道，烧伤护理机构，其他患者，以及患者的护理人员。该SBIR第一阶段项目涉及抗菌织物的制备，该抗菌织物用作感染控制的烧伤伤口敷料。抗微生物基团将共价连接到织物材料。该技术将取代目前使用的局部抗菌剂。目前的局部药剂已经显示出具有不期望的副作用，并且由于耐药微生物的出现，它们对感染控制的有效性持续下降。第一阶段项目的目标是制备一种抗菌织物，该织物对广谱常见烧伤伤口病原体有效，对人体皮肤细胞无细胞毒性，因此不会抑制愈合过程。

DESCRIPTION (provided by applicant): 100,000 - 300,000 hospitalizations occur annually in the United States as a result of an estimated two million people who suffer burn injuries. More than 12,000 of these two million will eventually die of burn-related infections. In fact, infections are the largest cause of death in burn patients. Burn wound infections can be traced to several sources including: the patient's own skin and gastrointestinal tract, the burn care facility, other patients, and from the patient's caregivers. This SBIR Phase I project concerns the preparation of an antimicrobial fabric to be used as a burn wound dressing for infection control. An antimicrobial group will be covalently linked to the fabric material. This technology will replace the currently employed topical antimicrobial agents. Current topical agents have been shown to have undesirable side effects and their effectiveness for infection control continues to decline due to the emergence of resistant microorganisms. The goal of this Phase I project is to prepare an antimicrobial fabric that is effective against a broad spectrum of the common burn wound pathogens and is not cytotoxic to human skin cells and therefore will not inhibit the healing process.